Abstract
Cancer is a disease that shows uncontrolled cell division and invasion in other tissues, resulting in high incidence and mortality worldwide. Classical chemotherapeutic agents have poor water solubility and lack of specificity, resulting in systemic toxicity and limitations of the maximum drug dose. Alternatively, the use of nanosized drug carriers overcomes these drawbacks and increase therapeutic efficacy of many chemotherapy drugs. Nanocarriers for drug delivery allows systems to combine properties for multiple functions. Here, cyclodextrins are of particular interest due to their good inclusion capability, excellent biocompatibility, and ability to self-assemble and form various stable nanoscale systems such as micellar aggregates, nanoreservoirs and nanoparticles for biomedical applications. These cyclodextrin-based nanosystems show several advantages in terms of stability, safety, the ability to encapsulate hydrophobic drugs and good in vivo tolerance.
Here we review cyclodextrin-based nanocarriers such as liposomes, nanoparticles, micelles for delivery of anticancer drugs in cancer therapy. We discuss preparation and characterization. We compare cyclodextrin-based nanocarrier groups for their potential in targeted delivery of anticancer agents such as chemotherapeutic drugs, and siRNA for cancer therapy or diagnosis. The major benefits are recognition of cancer cells and delivery of drugs to the target tissue, high antitumor efficacy and low adverse effects, prolonged blood circulation, higher drug loading, and controlled release. In vitro and in vivo studies performed in cell cultures and animal models have given promising results.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Agardan NB, Degim Z, Yilmaz S, Altintas L, Topal T (2016) The effectiveness of Raloxifene-loaded liposomes and Cochleates in breast cancer therapy. AAPS PharmSciTech 17:968–977. https://doi.org/10.1208/s12249-015-0429-3
Agueros M, Zabaleta V, Espuelas S, Campanero MA, Irache JM (2010) Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles. J Control Release 145:2–8. https://doi.org/10.1016/j.jconrel.2010.03.012
Alexiou C, Tietze R, Schreiber E, Jurgons R, Richter H, Trahms L, Rahn H, Odenbach S, Lyer S (2011) Cancer therapy with drug loaded magnetic nanoparticles-magnetic drug targeting. J Magn Magn Mater 323:1404–1407. https://doi.org/10.1016/j.jmmm.2010.11.059
Anton N, Benoit JP, Saulnier P (2008) Design and production of nanoparticles formulated from nano-emulsion templates-a review. J Control Release 128:185–199. https://doi.org/10.1016/j.jconrel.2008.02.007
Badruddoza AZ, Rahman MT, Ghosh S, Hossain MZ, Shi J, Hidajat K, Uddin MS (2013) β-Cyclodextrin conjugated magnetic, fluorescent silica core-shell nanoparticles for biomedical applications. Carbohydr Polym 95:449–457. https://doi.org/10.1016/j.carbpol.2013.02.046
Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC (2014) Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 66:2–25. https://doi.org/10.1016/j.addr.2013.11.009
Bilensoy E, Hincal AA (2009) Recent advances and future directions in amphiphilic cyclodextrin nanoparticles. Expert Opin Drug Deliv 6:1161–1173. https://doi.org/10.1517/17425240903222218
Bilensoy E, Gurkaynak O, Dogan AL, Hincal AA (2008a) Safety and efficacy of amphiphilic beta-cyclodextrin nanoparticles for paclitaxel delivery. Int J Pharm 347:163–170. https://doi.org/10.1016/j.ijpharm.2007.06.051
Bilensoy E, Gurkaynak O, Ertan M, Sen M, Hincal AA (2008b) Development of nonsurfactant cyclodextrin nanoparticles loaded with anticancer drug paclitaxel. J Pharm Sci 97:1519–1529. https://doi.org/10.1002/jps.21111
Boztas AO, Karakuzu O, Galante G, Ugur Z, Kocabas F, Altuntas CZ, Yazaydin AO (2013) Synergistic interaction of paclitaxel and curcumin with cyclodextrin polymer complexation in human cancer cells. Mol Pharm 10:2676–2683. https://doi.org/10.1021/mp400101k
Brannon-Peppas L, Blanchette JO (2004) Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 56:1649–1659. https://doi.org/10.1016/j.addr.2004.02.014
Brewster ME, Loftsson T (2007) Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev 59:645–666. https://doi.org/10.1016/j.addr.2007.05.012
Brigger I, Dubernet C, Couvreur P (2002) Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 54:631–651
Calixto GM, Bernegossi J, de Freitas LM, Fontana CR, Chorilli M (2016) Nanotechnology-based drug delivery systems for photodynamic therapy of cancer: a review. Molecules 21:342. https://doi.org/10.3390/molecules21030342
Carrier RL, Miller LA, Ahmed I (2007) The utility of cyclodextrins for enhancing oral bioavailability. J Control Release 123:78–99. https://doi.org/10.1016/j.jconrel.2007.07.018
Cavalcanti IMF, Mendonca EAM, Lira MCB, Honrato SB, Camara CA, Amorim RVS, Mendes J, Rabello MM, Hernandes MZ, Ayala AP, Santos-Magalhaes NS (2011) The encapsulation of beta-lapachone in 2-hydroxypropyl-beta-cyclodextrin inclusion complex into liposomes: a physicochemical evaluation and molecular modeling approach. Eur J Pharm Sci 44:332–340. https://doi.org/10.1016/j.ejps.2011.08.011
Chen Y, Chen C, Xiao Y, Zhang X, Chen Y (2015) Liposomes encapsulating 10-Hydroxycamptothecin-cyclodextrin complexes and their in vitro anti-tumor activities. J Nanosci Nanotechnol 15:3786–3795
Chidambaram M, Manavalan R, Kathiresan K (2011) Nanotherapeutics to overcome conventional cancer chemotherapy limitations. J Pharm Pharm Sci 14:67–77
Conte C, Scala A, Siracusano G, Leone N, Patane S, Ungaro F, Miro A, Sciortino MT, Quaglia F, Mazzaglia A (2014) Nanoassembly of an amphiphilic cyclodextrin and Zn(II)-phthalocyanine with the potential for photodynamic therapy of cancer. RSC Adv 4:43903–43911. https://doi.org/10.1039/c4ra07847k
Davis ME (2009) Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin. Adv Drug Deliv Rev 61:1189–1192. https://doi.org/10.1016/j.addr.2009.05.005
Davis ME, Brewster ME (2004) Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov 3:1023–1035. https://doi.org/10.1038/nrd1576
Deng C, Jiang Y, Cheng R, Meng F, Zhong Z (2012) Biodegradable polymeric micelles for targeted and controlled anticancer drug delivery: promises, progress and prospects. NanoToday 7:467–480
Dharap SS, Wang Y, Chandna P, Khandare JJ, Qiu B, Gunaseelan S, Sinko PJ, Stein S, Farmanfarmaian A, Minko T (2005) Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc Natl Acad Sci U S A 102:12962–12967. https://doi.org/10.1073/pnas.0504274102
di Cagno M, Terndrup Nielsen T, Lambertsen Larsen K, Kuntsche J, Bauer-Brandl A (2014) β-Cyclodextrin-dextran polymers for the solubilization of poorly soluble drugs. Int J Pharm 468:258–263. https://doi.org/10.1016/j.ijpharm.2014.04.029
Duchene D, Ponchel G, Wouessidjewe D (1999) Cyclodextrins in targeting. Application to nanoparticles. Adv Drug Deliv Rev 36:29–40
Elsabahy M, Nazarali A, Foldvari M (2011) Non-viral nucleic acid delivery: key challenges and future directions. Curr Drug Deliv 8:235–244
Erdogar N, Esendagli G, Nielsen TT, Sen M, Oner L, Bilensoy E (2016) Design and optimization of novel paclitaxel-loaded folate-conjugated amphiphilic cyclodextrin nanoparticles. Int J Pharm 509:375–390. https://doi.org/10.1016/j.ijpharm.2016.05.040
Erdoğar N, Esendağlı G, Nielsen TT, Esendaglı-Yılmaz G, Yöyen-Ermiş D, Erdoğdu B, Sargon MF, Eroglu H, Bilensoy E (2017) Therapeutic efficacy of folate receptor-targeted amphiphilic cyclodextrin nanoparticles as a novel vehicle for paclitaxel delivery in breast cancer. J Drug Target. https://doi.org/10.1080/1061186X.2017.1339194
Evans JC, Malhotra M, Guo J, O'Shea JP, Hanrahan K, O'Neill A, Landry WD, Griffin BT, Darcy R, Watson RW, O'Driscoll CM (2016) Folate-targeted amphiphilic cyclodextrin.siRNA nanoparticles for prostate cancer therapy exhibit PSMA mediated uptake, therapeutic gene silencing in vitro and prolonged circulation in vivo. Nanomedicine 12:2341–2351. https://doi.org/10.1016/j.nano.2016.06.014
Farokhzad OC, Langer R (2006) Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev 58:1456–1459. https://doi.org/10.1016/j.addr.2006.09.011
Farokhzad OC, Langer R (2009) Impact of nanotechnology on drug delivery. ACS Nano 3:16–20. https://doi.org/10.1021/nn900002m
Fitzgerald KA, Malhotra M, Gooding M, Sallas F, Evans JC, Darcy R, O'Driscoll CM (2016) A novel, anisamide-targeted cyclodextrin nanoformulation for siRNA delivery to prostate cancer cells expressing the sigma-1 receptor. Int J Pharm 499:131–145. https://doi.org/10.1016/j.ijpharm.2015.12.055
Frank DW, Gray JE, Weaver RN (1976) Cyclodextrin nephrosis in the rat. Am J Pathol 83:367–382
Garland MJ, Cassidy CM, Woolfson D, Donnelly RF (2009) Designing photosensitizers for photodynamic therapy: strategies, challenges and promising developments. Future Med Chem 1:667–691. https://doi.org/10.4155/fmc.09.55
Gaur S, Chen L, Yen T, Wang Y, Zhou B, Davis M, Yen Y (2012) Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer. Nanomedicine 8:721–730. https://doi.org/10.1016/j.nano.2011.09.007
Gidwani B, Vyas A (2014) Synthesis, characterization and application of epichlorohydrin-beta-cyclodextrin polymer. Colloids Surf B Biointerfaces 114:130–137. https://doi.org/10.1016/j.colsurfb.2013.09.035
Gidwani B, Vyas A (2015) A comprehensive review on cyclodextrin-based carriers for delivery of chemotherapeutic cytotoxic anticancer drugs. Biomed Res Int 2015:198268. https://doi.org/10.1155/2015/198268
Gillet A, Grammenos A, Compere P, Evrard B, Piel G (2009) Development of a new topical system: drug-in-cyclodextrin-in-deformable liposome. Int J Pharm 380:174–180. https://doi.org/10.1016/j.ijpharm.2009.06.027
Golden PL, Huwyler J, Pardridge WM (1998) Treatment of large solid tumors in mice with daunomycin-loaded sterically stabilized liposomes. Drug Deliv 5:207–212. https://doi.org/10.3109/10717549809052036
Guo J, Bourre L, Soden DM, O'Sullivan GC, O'Driscoll C (2011) Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics? Biotechnol Adv 29:402–417. https://doi.org/10.1016/j.biotechadv.2011.03.003
Hak S, Helgesen E, Hektoen HH, Huuse EM, Jarzyna PA, Mulder WJ, Haraldseth O, Davies Cde L (2012) The effect of nanoparticle polyethylene glycol surface density on ligand-directed tumor targeting studied in vivo by dual modality imaging. ACS Nano 6:5648–5658. https://doi.org/10.1021/nn301630n
He Q, Wu W, Xiu KM, Zhang Q, Xu FJ, Li JS (2013) Controlled drug release system based on cyclodextrin-conjugated poly(lactic acid)-b-poly(ethylene glycol) micelles. Int J Pharm 443:110–119. https://doi.org/10.1016/j.ijpharm.2012.12.042
Hirayama F, Uekama K (1999) Cyclodextrin-based controlled drug release system. Adv Drug Deliv Rev 36:125–141
Huarte J, Espuelas S, Lai Y, He B, Tang J, Irache JM (2016) Oral delivery of camptothecin using cyclodextrin/poly(anhydride) nanoparticles. Int J Pharm 506:116–128. https://doi.org/10.1016/j.ijpharm.2016.04.045
Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ (2005) Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 65:8984–8992. https://doi.org/10.1158/0008-5472.CAN-05-0565
Ito A, Shinkai M, Honda H, Kobayashi T (2005) Medical application of functionalized magnetic nanoparticles. J Biosci Bioeng 100:1–11. https://doi.org/10.1263/jbb.100.1
Kim H, Kim S, Park C, Lee H, Park HJ, Kim C (2010) Glutathione-induced intracellular release of guests from mesoporous silica nanocontainers with cyclodextrin gatekeepers. Adv Mater 22:4280–4283. https://doi.org/10.1002/adma.201001417
Kobayashi M, Wood PA, Hrushesky WJ (2002) Circadian chemotherapy for gynecological and genitourinary cancers. Chronobiol Int 19:237–251
Kwon GS, Okano T (1996) Polymeric micelles as new drug carriers. Adv Drug Deliv Rev 21:107–116. https://doi.org/10.1016/S0169-409x(96)00401-2
Lakkakula JR, Macedo Krause RW (2014) A vision for cyclodextrin nanoparticles in drug delivery systems and pharmaceutical applications. Nanomedicine (Lond) 9:877–894. https://doi.org/10.2217/nnm.14.41
Laza-Knoerr AL, Gref R, Couvreur P (2010) Cyclodextrins for drug delivery. J Drug Target 18:645–656. https://doi.org/10.3109/10611861003622552
Lemos-Senna E, Wouessidjewe D, Lesieur S, Puisieux F, Couarraze G, Duchene D (1998) Evaluation of the hydrophobic drug loading characteristics in nanoprecipitated amphiphilic cyclodextrin nanospheres. Pharm Dev Technol 3:85–94. https://doi.org/10.3109/10837459809028482
Lim HJ, Cho EC, Shim J, Kim DH, An EJ, Kim J (2008) Polymer-associated liposomes as a novel delivery system for cyclodextrin-bound drugs. J Colloid Interface Sci 320:460–468. https://doi.org/10.1016/j.jcis.2008.01.025
Lin IC, Fang JH, Lin CT, Sung SY, Su YL, Hu SH (2016) Enhanced targeted delivery of cyclodextrin-based supermolecules by core-shell nanocapsules for magnetothermal chemotherapy. Macromol Biosci 16:1273–1286. https://doi.org/10.1002/mabi.201600131
Liu T, Xue W, Ke B, Xie MQ, Ma D (2014) Star-shaped cyclodextrin-poly(l-lysine) derivative co-delivering docetaxel and MMP-9 siRNA plasmid in cancer therapy. Biomaterials 35:3865–3872. https://doi.org/10.1016/j.biomaterials.2014.01.040
Loftsson T, Brewster ME (2011) Pharmaceutical applications of cyclodextrins: effects on drug permeation through biological membranes. J Pharm Pharmacol 63:1119–1135. https://doi.org/10.1111/j.2042-7158.2011.01279.x
Loftsson T, Duchene D (2007) Cyclodextrins and their pharmaceutical applications. Int J Pharm 329:1–11. https://doi.org/10.1016/j.ijpharm.2006.10.044
Loftssona T, Jarvinen T (1999) Cyclodextrins in ophthalmic drug delivery. Adv Drug Deliv Rev 36:59–79
Lorence A, Nessler CL (2004) Camptothecin, over four decades of surprising findings. Phytochemistry 65:2735–2749. https://doi.org/10.1016/j.phytochem.2004.09.001
Lourenço LM, Pereira PM, Maciel E, Valega M, Domingues FM, Domingues MR, Neves MG, Cavaleiro JA, Fernandes R, Tome JP (2014) Amphiphilic phthalocyanine-cyclodextrin conjugates for cancer photodynamic therapy. Chem Commun (Camb) 50:8363–8366. https://doi.org/10.1039/c4cc02226b
Ma M, DeQuan L (1999) New organic nanoporous polymers and their inclusion complexes. Chem Mater 11:872–874
Maeda H, Bharate GY, Daruwalla J (2009) Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm 71:409–419. https://doi.org/10.1016/j.ejpb.2008.11.010
Maestrelli F, Gonzalez-Rodriguez ML, Rabasco AM, Mura P (2006) Effect of preparation technique on the properties of liposomes encapsulating ketoprofen-cyclodextrin complexes aimed for transdermal delivery. Int J Pharm 312:53–60. https://doi.org/10.1016/j.ijpharm.2005.12.047
Malingre MM, Beijnen JH, Schellens JH (2001) Oral delivery of taxanes. Investig New Drugs 19:155–162
Matsuda H, Arima H (1999) Cyclodextrins in transdermal and rectal delivery. Adv Drug Deliv Rev 36:81–99
Mazzaglia A, Angelini N, Darcy R, Donohue R, Lombardo D, Micali N, Sciortino MT, Villari V, Scolaro LM (2003) Novel heterotopic colloids of anionic porphyrins entangled in cationic amphiphilic cyclodextrins: spectroscopic investigation and intracellular delivery. Chemistry 9:5762–5769. https://doi.org/10.1002/chem.200304861
Mccormack B, Gregoriadis G (1994) Drugs-in-cyclodextrins-in-liposomes - a novel concept in drug-delivery. Int J Pharm 112:249–258. https://doi.org/10.1016/0378-5173(94)90361-1
McCormack B, Gregoriadis G (1996) Comparative studies of the fate of free and liposome-entrapped hydroxypropyl-beta-cyclodextrin/drug complexes after intravenous injection into rats: implications in drug delivery. Biochim Biophys Acta 1291:237–244
Merisko-Liversidge E, Liversidge GG, Cooper ER (2003) Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci 18:113–120
Merkus FW, Verhoef JC, Marttin E, Romeijn SG, van der Kuy PH, Hermens WA, Schipper NG (1999) Cyclodextrins in nasal drug delivery. Adv Drug Deliv Rev 36:41–57
Minko T (2004) Drug targeting to the colon with lectins and neoglycoconjugates. Adv Drug Deliv Rev 56:491–509. https://doi.org/10.1016/j.addr.2003.10.017
Minko T, Dharap SS, Pakunlu RI, Wang Y (2004) Molecular targeting of drug delivery systems to cancer. Curr Drug Targets 5:389–406
Mitsunaga M, Ogawa M, Kosaka N, Rosenblum LT, Choyke PL, Kobayashi H (2011) Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med 17:1685–1691. https://doi.org/10.1038/nm.2554
Mora-Huertas CE, Fessi H, Elaissari A (2010) Polymer-based nanocapsules for drug delivery. Int J Pharm 385:113–142. https://doi.org/10.1016/j.ijpharm.2009.10.018
Ohyama A, Higashi T, Motoyama K, Arima H (2016) In vitro and in vivo tumor-targeting siRNA delivery using folate-PEG-appended dendrimer (G4)/α-cyclodextrin conjugates. Bioconjug Chem 27:521–532. https://doi.org/10.1021/acs.bioconjchem.5b00545
Peltier S, Oger JM, Lagarce F, Couet W, Benoit JP (2006) Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm Res 23:1243–1250. https://doi.org/10.1007/s11095-006-0022-2
Pizzimenti S, Daga M, Ciamporcero E, Toaldo C, Pettazzoni P, Osella-Abate S, Novelli M, Minelli R, Bisazza A, Gamba P, Testa G, Ullio C, Ferruti P, Ranucci E, Bernengo MG, Ferretti C, Dianzani C, Biasi F, Barrera G, Cavalli R (2015) Improved anti-tumoral therapeutic efficacy of 4-hydroxynonenal incorporated in novel lipid nanocapsules in 2D and 3D models. J Biomed Nanotechnol 11:2169–2185. https://doi.org/10.1166/jbn.2015.2131
Ross RW, Small EJ (2002) Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol 167:1952–1956
Schluep T, Hwang J, Cheng J, Heidel JD, Bartlett DW, Hollister B, Davis ME (2006) Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res 12:1606–1614. https://doi.org/10.1158/1078-0432.CCR-05-1566
Sehouli J, Stengel D, Elling D, Ortmann O, Blohmer J, Riess H, Lichtenegger W, Ovarian Cancer Study Group of the Nordostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO) (2002) First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study. Gynecol Oncol 85:321–326. https://doi.org/10.1006/gyno.2002.6623
Simões SM, Veiga F, Ribeiro AC, Figueiras AR, Taboada P, Concheiro A, Alvarez-Lorenzo C (2014) Supramolecular gels of poly-α-cyclodextrin and PEO-based copolymers for controlled drug release. Eur J Pharm Biopharm 87:579–588. https://doi.org/10.1016/j.ejpb.2014.04.006
Simões SM, Rey-Rico A, Concheiro A, Alvarez-Lorenzo C (2015) Supramolecular cyclodextrin-based drug nanocarriers. Chem Commun (Camb) 51:6275–6289. https://doi.org/10.1039/c4cc10388b
Sortino S, Mazzaglia A, Scolaro LM, Merlo FM, Valveri V, Sciortino MT (2006) Nanoparticles of cationic amphiphilic cyclodextrins entangling anionic porphyrins as carrier-sensitizer system in photodynamic cancer therapy. Biomaterials 27:4256–4265. https://doi.org/10.1016/j.biomaterials.2006.03.035
Sun L, Zhou DS, Zhang P, Li QH, Liu P (2015) Gemcitabine and gamma-cyclodextrin/docetaxel inclusion complex-loaded liposome for highly effective combinational therapy of osteosarcoma. Int J Pharm 478:308–317. https://doi.org/10.1016/j.ijpharm.2014.11.052
Szente L, Szejtli J (1999) Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Adv Drug Deliv Rev 36:17–28
Tarasi R, Khoobi M, Niknejad H, Ramazani A, Ma'mani L, Bahadorikhalili S, Shafiee A (2016) Beta-cyclodextrin functionalized poly (5-amidoisophthalicacid) grafted Fe3O4 magnetic nanoparticles: a novel biocompatible nanocomposite for targeted docetaxel delivery. J Magn Magn Mater 417:451–459. https://doi.org/10.1016/j.jmmm.2016.05.080
Uekama K, Hirayama F, Irie T (1998) Cyclodextrin drug carrier systems. Chem Rev 98:2045–2076
Ünal H, d’Angelo I, Pagano E, Borrelli F, Izzo A, Ungaro F, Quaglia F, Bilensoy E (2015a) Core-shell hybrid nanocapsules for oral delivery of camptothecin: formulation development, in vitro and in vivo evaluation. J Nanopart Res 17:42. https://doi.org/10.1007/s11051–014–2838-8
Ünal H, Ozturk N, Bilensoy E (2015b) Formulation development, stability and anticancer efficacy of core-shell cyclodextrin nanocapsules for oral chemotherapy with camptothecin. Beilstein J Org Chem 11:204–212. https://doi.org/10.3762/bjoc.11.22
van der Meel R, Vehmeijer LJ, Kok RJ, Storm G, van Gaal EV (2013) Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. Adv Drug Deliv Rev 65:1284–1298. https://doi.org/10.1016/j.addr.2013.08.012
Wang Y, Li X, Wang L, Xu Y, Cheng X, Wei P (2011) Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery. Int J Nanomedicine 6:1497–1507. https://doi.org/10.2147/IJN.S21097
Weiss GJ, Chao J, Neidhart JD, Ramanathan RK, Bassett D, Neidhart JA, Choi CH, Chow W, Chung V, Forman SJ, Garmey E, Hwang J, Kalinoski DL, Koczywas M, Longmate J, Melton RJ, Morgan R, Oliver J, Peterkin JJ, Ryan JL, Schluep T, Synold TW, Twardowski P, Davis ME, Yen Y (2013) First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. Investig New Drugs 31:986–1000. https://doi.org/10.1007/s10637-012-9921-8
Wicki A, Witzigmann D, Balasubramanian V, Huwyler J (2015) Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release 200:138–157. https://doi.org/10.1016/j.jconrel.2014.12.030
Xu X, Ho W, Zhang X, Bertrand N, Farokhzad O (2015) Cancer nanomedicine: from targeted delivery to combination therapy. Trends Mol Med 21:223–232. https://doi.org/10.1016/j.molmed.2015.01.001
Yao HJ, Ju RJ, Wang XX, Zhang Y, Li RJ, Yu Y, Zhang L, Lu WL (2011) The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery. Biomaterials 32:3285–3302. https://doi.org/10.1016/j.biomaterials.2011.01.038
Ye YJ, Wang Y, Lou KY, Chen YZ, Chen R, Gao F (2015) The preparation, characterization, and pharmacokinetic studies of chitosan nanoparticles loaded with paclitaxel/dimethyl-beta-cyclodextrin inclusion complexes. Int J Nanomedicine 10:4309–4319. https://doi.org/10.2147/IJN.S83508
Yu S, Zhang Y, Wang X, Zhen X, Zhang Z, Wu W, Jiang X (2013) Synthesis of paclitaxel-conjugated β-cyclodextrin polyrotaxane and its antitumor activity. Angew Chem Int Ed Engl 52:7272–7277. https://doi.org/10.1002/anie.201301397
Zeng J, Huang H, Liu S, Xu H, Huang J, Yu J (2013) Hollow nanosphere fabricated from β-cyclodextrin-grafted α,β-poly(aspartic acid) as the carrier of camptothecin. Colloids Surf B Biointerfaces 105:120–127. https://doi.org/10.1016/j.colsurfb.2012.12.024
Zhang Z, Ding JX, Chen XF, Xiao CS, He CL, Zhuang XL, Chen L, Chen XS (2013) Intracellular pH-sensitive supramolecular amphiphiles based on host-guest recognition between benzimidazole and beta-cyclodextrin as potential drug delivery vehicles. Polym Chem 4:3265–3271. https://doi.org/10.1039/c3py00141e
Zhang L, Lu JF, Jin YM, Qiu LY (2014) Folate-conjugated beta-cyclodextrin-based polymeric micelles with enhanced doxorubicin antitumor efficacy. Colloids Surf B Biointerfaces 122:260–269. https://doi.org/10.1016/j.colsurfb.2014.07.005
Zhao D, Zhao X, Zu Y, Li J, Zhang Y, Jiang R, Zhang Z (2010) Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles. Int J Nanomedicine 5:669–677
Acknowledgements
Authors would like to acknowledge TUBITAK Scientific Research Project 112S538 for financial support of this study. Nazlı Erdoğar has been supported by TUBITAK in the framework of 2214-A Foreign Postgraduate Research Scholarship Programme for her studies in Aalborg University, Denmark.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Erdoğar, N., Bilensoy, E. (2018). Cyclodextrin-Based Nanosystems in Targeted Cancer Therapy. In: Fourmentin, S., Crini, G., Lichtfouse, E. (eds) Cyclodextrin Applications in Medicine, Food, Environment and Liquid Crystals. Environmental Chemistry for a Sustainable World, vol 17. Springer, Cham. https://doi.org/10.1007/978-3-319-76162-6_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-76162-6_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-76161-9
Online ISBN: 978-3-319-76162-6
eBook Packages: Earth and Environmental ScienceEarth and Environmental Science (R0)